Welcome subscribers,
For life sciences companies, there is a distinctive relationship between funding, headcount and demand for R&D space and in our latest analysis, we reveal that every €1 billion in funding drives demand over time for c.17,000 square metres of such space. Read our in-depth analysis to see how it works.
In this edition, we also bring you news of deals (new buildings, extensions, sales and leases):
✅ France: new real estate fund targets life sciences
✅ Germany: capex indicates confidence
✅ Netherlands: Novo Nordisk on the move
✅ UK: Prologis commits to Cambridge
Read more below for all the details.
How funding drives headcount and demand for R&D space
Read the full articleA message from our sponsor Backbone Connect:
Was this email forwarded to you? Did you know that you can subscribe to Life Sciences Real Estate and get access to all our resources?
New and extended assets
FRANCE PARIS
Q4 2024 saw the start of construction at The MIX at Paris-Saclay. The building extends to 15,000 sq m over five floors, offering laboratory, office and production space. The MIX also offers centralised management of special gases (CO2, nitrogen gas and compressed air) plus dedicated areas for waste management. Completion is expected in Q3 2026. The MIX will be the second building developed and managed by Kadans Science Partner in France. Its opening is scheduled one year after the delivery of The HIVE, located within the Campus Grand Parc in Villejuif and dedicated to innovation in oncology.
GERMANY BERLIN
In October 2024, SIRIO Pharma announced an investment of €16 million (£13 million) in a new automated packaging facility at its Pritzwalk campus near Berlin, bringing its total site investment to €19 million (£16 million) over five years. The facility features modern bottling and blistering lines, enabling SIRIO to provide comprehensive services from formulation to final packaging. Operating under pharmaceutical GMP standards for both human and veterinary products, the site integrates with the adjacent manufacturing facility. The automated lines include a high-speed bottling system capable of producing 5 million bottles annually (75ml to 400ml) and a blister line with capacity for 20 million packs yearly across ten formats.
GERMANY LAUPHEIM
Rentschler Biopharma SE announced in October 2024 the construction of a new buffer media station at its Laupheim headquarters, located in Baden-Württemberg. A buffer media station is a specialised facility that prepares and stores the liquid solutions (buffers) needed for biopharmaceutical manufacturing, ensuring consistent product quality and efficient production. The new 3,400 sq m (36,600 sq ft) facility extends over four floors and is set to open in 2028. Rentschler Biopharma SE is a German family-owned contract development and manufacturing organisation (CDMO) that specialises in producing biopharmaceuticals and advanced therapy medicinal products for other companies.
